Skip to main content
Clinical Trials/NCT04228809
NCT04228809
Completed
Not Applicable

Long-term Efficacy of Transcranial Direct Current Stimulation in Chronic Migraine With Medication Overuse: a Phase III, Placebo Controlled, Randomised Clinical Trial (Edisom)

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta0 sites135 target enrollmentDecember 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Migraine Disorders
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Enrollment
135
Primary Endpoint
days of headache per month (long-term)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Transcranial direct current stimulation (tDCS) was suggested to provide beneficial effects in chronic migraine (CM), a condition often associated with medication overuse (MO) for which no long-term therapy is available.

Detailed Description

We conducted a randomized controlled trial to assess long-term efficacy of tDCS. Adults diagnosed with CM and MO were assigned to receive in a 1:1:1 ratio anodal, cathodal, or sham tDCS daily for five consecutive days, along with standardized drug withdrawal protocol with intravenous administration of dexamethasone 4 mg and ademetionine 200 mg in saline solution, and oral bromazepam 1.5 mg three times daily. Primary outcome was 50% reduction of days of headache per month at 12 months. Co-secondary outcomes were 50% reduction of days of headache per month at 6 months, reduction of analgesic intake per month, and change in disability and quality of life, catastrophizing, depression, state and trait anxiety, dependence attitude and allodynia intensity. Patients were not allowed to take any migraine prophylaxis drug for the entire study period.

Registry
clinicaltrials.gov
Start Date
December 1, 2015
End Date
May 30, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • chronic migraine with medication overuse according to the International Headache Society criteria. Diagnosis was confirmed on the basis of a daily headache diary that all eligible patients filled out in the last month prior to the enrollment. Patients should have failed at least two prophylaxis therapies. Written informed consent.

Exclusion Criteria

  • known diagnosis of major depression or other major psychiatric disorders identified after psychiatric consultation, cardiac pace maker, clips for previous head surgery, cochlear implant, history of epilepsy, known idiopathic intracranial hypertension, harmful alcohol consumption, pregnancy.

Outcomes

Primary Outcomes

days of headache per month (long-term)

Time Frame: 12 months

no. patients with 50% reduction of days of headache per month

Secondary Outcomes

  • analgesic intake per month(6 and 12 months)
  • state and trait anxiety(6 and 12 months)
  • dependence attitude(6 and 12 months)
  • catastrophizing attitude(6 and 12 months)
  • allodynia intensity(6 and 12 months)
  • days of headache per month (mid-term)(6 months)
  • disability(6 and 12 months)
  • depression(6 and 12 months)

Similar Trials